tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Perspective Therapeutics Highlights Progress in Radioligand Oncology Pipeline
PremiumCompany AnnouncementsPerspective Therapeutics Highlights Progress in Radioligand Oncology Pipeline
1M ago
Undervalued Radiopharma Pipeline and Manufacturing Platform Underpin Buy Rating and $18 Target
Premium
Ratings
Undervalued Radiopharma Pipeline and Manufacturing Platform Underpin Buy Rating and $18 Target
1M ago
Perspective Therapeutics outlines 2026 clinical and manufacturing priorities
Premium
Company Announcements
Perspective Therapeutics outlines 2026 clinical and manufacturing priorities
1M ago
Perspective Therapeutics assumed with a Buy at Truist
PremiumThe FlyPerspective Therapeutics assumed with a Buy at Truist
3M ago
Perspective Therapeutics price target lowered to $7 from $18 at UBS
Premium
The Fly
Perspective Therapeutics price target lowered to $7 from $18 at UBS
3M ago
Buy Rating Affirmed for Perspective Therapeutics Amid Promising Developments in VMT-α-NET Program
Premium
Ratings
Buy Rating Affirmed for Perspective Therapeutics Amid Promising Developments in VMT-α-NET Program
3M ago
Buy Rating for Perspective Therapeutics: Promising Pipeline and Financial Stability
PremiumRatingsBuy Rating for Perspective Therapeutics: Promising Pipeline and Financial Stability
3M ago
Buy Rating for Perspective Therapeutics: Promising Pb-212 Pipeline and Acquisition Potential
Premium
Ratings
Buy Rating for Perspective Therapeutics: Promising Pb-212 Pipeline and Acquisition Potential
3M ago
Perspective Therapeutics price target lowered to $13 from $14 at Oppenheimer
Premium
The Fly
Perspective Therapeutics price target lowered to $13 from $14 at Oppenheimer
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100